SEC Form 4 · accession 0001645627-18-000078
ENDONOVO THERAPEUTICS, INC. · ENDV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Scott Mann
Officer — President
Period of report
Dec 7, 2018
Accepted (ET)
Dec 11, 2018 · 5:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001528172
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 7, 2018 | P | 2,000 | $0.0267 | A | 26,315,698 | D | |
| Common Stock | Dec 7, 2018 | P | 2,000 | $0.0267 | A | 26,317,698 | D | |
| Common Stock | Dec 7, 2018 | P | 2,000 | $0.0258 | A | 26,319,698 | D | |
| Common Stock | Dec 7, 2018 | P | 1,000 | $0.0256 | A | 26,320,698 | D | |
| Common Stock | Dec 10, 2018 | P | 1,000 | $0.0227 | A | 26,321,698 | D | |
| Common Stock | Dec 10, 2018 | P | 1,000 | $0.0227 | A | 26,322,698 | D | |
| Common Stock | Dec 10, 2018 | P | 2,000 | $0.0228 | A | 26,324,698 | D | |
| Common Stock | Dec 10, 2018 | P | 2,000 | $0.0228 | A | 26,326,698 | D | |
| Common Stock | Dec 10, 2018 | P | 2,000 | $0.0228 | A | 26,328,698 | D | |
| Common Stock | Dec 10, 2018 | P | 2,000 | $0.0224 | A | 26,330,698 | D | |
| Common Stock | Dec 10, 2018 | P | 2,000 | $0.022 | A | 26,332,698 | D | |
| Common Stock | Dec 10, 2018 | P | 2,000 | $0.0238 | A | 26,334,698 | D | |
| Common Stock | Dec 10, 2018 | P | 1,000 | $0.0239 | A | 26,335,698 | D | |
| Common Stock | Dec 10, 2018 | P | 1,000 | $0.0233 | A | 26,336,698 | D | |
| Common Stock | Dec 10, 2018 | P | 2,000 | $0.0233 | A | 26,338,698 | D | |
| Common Stock | Dec 10, 2018 | P | 100 | $0.0233 | A | 26,338,798 | D | |
| Common Stock | Dec 10, 2018 | P | 1,000 | $0.0233 | A | 26,339,798 | D | |
| Common Stock | Dec 10, 2018 | P | 100 | $0.0233 | A | 26,339,898 | D | |
| Common Stock | Dec 10, 2018 | P | 1,000 | $0.0233 | A | 26,340,898 | D | |
| Common Stock | Dec 10, 2018 | P | 1,000 | $0.0239 | A | 26,341,898 | D |
Table II — derivative securities
No Table II lines on this filing.